Zheng Zhao

High Magnetic Field Lab, CAS
P.O. Box 1110, 350 Shushanhu Road, Hefei, 230031

Tel: 0551-65591485
Email: zhzhao@hmfl.ac.cn

 

 

 

EDUCATION BACKGROUND

1995 .09– Jul.1999.07, B. S. Department of Chemistry, Wuhan University, P. R. China.

2002.10 – Dec.2008.12, Ph. D. School of Life Science, University of Science and Technology of China.

 

RESEARCH EXPERIENCE

2009.05 - 2011. 09 Research Associate, Department of Chemistry, Hongkong University, Hongkong

2011.10 – 2012.02 Assistant Professors, High Magnetic Field Lab, CAS, China.

2012.03 – now Associate Professors, High Magnetic Field Lab, CAS, China.

 

RESEARCH INTEREREST

Rational computer-aided drug design has been characterized in the process of drug discovery, however which has been of limited success. My research is involved in developing new tools, integrates a number of existing tools and avails vast amounts of genotypic and molecular phenotypic data generated by omics techniques. The aim is to study complex diseases and personalized medicines and design new lead molecules. I am pursuing multi-faceted projects, either computer science or biology/chemistry oriented structural bioinformatics, drug bioinformatics, enzymatics et al. Any interests, you can contact me.

 

PUBLICATIONS

  1. Xiaofei Liang, Xiaochuan Liu, Beilei Wang, Fengming Zou, Aoli Wang, Shuang Qi, Cheng Chen,  Zheng Zhao, Wenchao Wang, Ziping Qi, Fengchao Lv, Zhenquan Hu, Li Wang, Shanchun Zhang, Qingsong Liu, Jing Liu，Discovery of 2-((3-amino-4-methylphenyl) amino)-N-(2-methyl-5-(3-(trifluoromethyl) benzamido) phenyl)-4-(methylamino) pyrimidine-5-carboxamide (CHMFL-ABL-053) as a potent, selective and orally available BCR-ABL/SRC/p38 kinase inhibitor for Chronic Myeloid Leukemia，J. Med. Chem., DOI: 10.1021/acs.jmedchem.5b01618
  2. Xixiang Li, Aoli Wang, Kailin Yu, Ziping Qi, Cheng Chen, Wenchao Wang, Chen Hu, Hong Wu, JiaxinWu, Zheng Zhao, Juan Liu, Fengming Zou, Li Wang, Beilei Wang, Wei Wang, Shanchun Zhang, JingLiu, and Qingsong Liu iscovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia. J. Med. Chem.， 2015, December 2, DOI: 10.1021/acs.jmedchem.5b01611
  3.  JingLiu, and Qingsong Liu iscovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia. J. Med. Chem.， 2015, December 2, DOI: 10.1021/acs.jmedchem.5b01611
  4. Hong Wu, Aoli Wang, Wei Zhang, Beilei Wang, Cheng Chen,Wenchao Wang, Chen Hu, Zi Ye, Zheng Zhao, Li Wang, Xixiang Li, Kailin Yu,Juan Liu, Jiaxin Wu, Xiao-E Yan, Peng Zhao, Jinhua Wang, Chu Wang,Ellen L. Weisberg, Nathanael S. Gray, Cai-Hong Yun, Jing Liu, Liang Chen,Liu Qingsong. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells.Oncotarget, 2015, Sep 5.
  5. Hong Wu, Chen Hu, Aoli Wang, Ellen L. Weisberg, Yongfei Chen, Cai-Hong Yun, Wenchao Wang, Yan Liu, Xiaochuan Liu, Bei Tian, Jinhua Wang, Zheng Zhao, Yanke Liang, Binhua Li, Li Wang, Beilei Wang, Cheng Chen, Sara J. Buhrlage, Ziping Qi, Fengming Zou, Atsushi Nonami, Yuyang Li, Stacey M. Fernandes, Sophia Adamia, Richard M. Stone, Ilene A. Galinsky, Xianhuo Wang, Guang Yang, James D. Griffin, Jennifer R. Brown, Michael J. Eck, Jing Liu, Nathanael S. Gray. Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia.Leukemia, 2015, Jul 13. doi:10.1038/leu.2015.180.
  6. Wu Hong, Hu Chen, Wang Aoli, E L Weisberg, Wang Wenchao, Chen Cheng, Zheng Zhao, Yu Kailin, Liu Juan, Wu Jiaxin, A Nonami, Wang Li, Wang Beilei, R M Stone, S Liu, J D Griffin,Liu Jing and Liu Qingsong. Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia, 2015,  Jul 3. doi: 10.1038/leu.2015.175. 
  7. Moccia M, Liu Q, Guida T, Federico G, Brescia A, Zheng Zhao, Choi HG, Deng X, Tan L, Wang J, Billaud M, Gray NS, Carlomagno F, Santoro M. Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase. PLoS One, 2015, Jun 5;10(6):e0128364. doi: 10.1371/journal.pone.0128364.
  8. Yinliang Zhang,Zheng Zhao*and Haiyan Liu*Deriving chemically essential interactions based on active site alignments and quantum chemical calculations: a case study on glycoside hydrolases. ACS Catalysis.,2015, 5, 2559−2572. (co-Correspondence author)
  9. Yinliang Zhang, Zheng Zhao* and Haiyan Liu* Deriving chemically essential interactions based on active site alignments and quantum chemical calculations: a case study on glycoside hydrolases. ACS Catalysis. 2015. DOI: 10.1021/cs501709d (co-Correspondence author)
  10. Zhao Zheng, Wu H, Wang L, Liu Y, Knapp S, Liu Q. Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?  ACS Chem. Biol. 2014, 9, 1230−1241.
  11. Wu H, Wang W, Liu F, Weisberg EE, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Zheng, McMillin DW, Hu C, Li H, Wang J, Liang Y, Buhrlage SJ, Liang J, Liu J, Yang G, Brwon JR, Treon SP, Mitsiades CS, Griffin J, Liu Q, Gray NS. Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma. ACS Chem. Biol., 2014, 9 (5), pp 1086–1091.
  12. Hyung-Gu Kim, Li Tan, Ellen L Weisberg, Feiyang Liu, Peter Canning, Hwan Geun Choi, Scott A Ezell, Hong Wu, Zheng Zhao, and Jinhua Wang, Discovery of a potent and selective ddr1 receptor tyrosine kinase inhibitor, ACS Chem. Biol., 8 (10),2145–2150, 2013.
  13. Feiyang Liu, Xin Zhang, Ellen Weisberg, Sen Chen, Wooyoung Hur, Hong Wu, Zheng Zhao, Wenchao Wang, Mao Mao, and Changmeng Cai, Discovery of a selective irreversible bmx inhibitor for prostate cancer, ACS Chem. Biol., 8(7), 1423-1428, 2013.
  14. Liu Q, Sabnis Y, Zhao Zheng, Zhang T, Buhrlage SJ, Jones LH, Gray NS*. Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol.  20(2):146-59. 2013.
  15. Choi HG, Zhang J, Deng X, Hatcher JM, Patricelli MP, Zhao Zheng, Alessi DR, Gray NS. Brain Penetrant LRRK2 Inhibitor. ACS Med. Chem. Lett. 3(8):658-662. 2012.
  16. Weisberg E, Liu Q, Nelson E, Kung AL, Christie AL, Bronson R, Sattler M, Sanda T, Zhao Zheng, Hur W, Mitsiades C, Smith R, Daley JF, Stone R, Galinsky I, Griffin JD, Gray NS. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors, and JAK inhibitors. Leukemia. 26(10):2233-44. 2012.
  17. Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, Wang J, Ni J, Patricelli MP, Vogel K, Riddle S, Waller DL, Traynor R, Sanda T, Zhao Zheng, Kang SA, Zhao J, Look AT, Sorger PK, Sabatini DM, Gray NS*. Kinome-wide selectivity profiling of ATP-competitive mTOR (mammalian target of rapamycin) inhibitors and characterization of their binding kinetics. J. Biol. Chem. 287(13):9742-52. 2012.
  18. Zheng Zhao, Haiyan Liu*.  A QM/MM study on the catalysis of the pyridoxal 5'-phosphate-dependent enzyme L-serine dehydratase.  J. Phys. Chem. B. 112,13091. 2008.